Last reviewed · How we verify
recombinant B-type, natriuretic peptide
Recombinant B-type natriuretic peptide, developed by the University of Texas Southwestern Medical Center, is a synthetic version of a naturally occurring hormone that helps regulate blood pressure and fluid balance. This drug is not yet approved by the FDA and is currently in the research and development phase. It is being evaluated for its potential to treat heart failure and other cardiovascular conditions. The drug's mechanism involves binding to specific receptors to promote vasodilation and natriuresis, which can help reduce the workload on the heart. Despite its promising therapeutic potential, the drug has not yet been fully characterized in terms of safety and efficacy, and further clinical trials are needed.
At a glance
| Generic name | recombinant B-type, natriuretic peptide |
|---|---|
| Also known as | Nesiritide |
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Natriuretic peptides |
| Target | Natriuretic peptide receptor-A (NPR-A) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Key clinical trials
- Recombinant Human Brain Natriuretic Peptide for the Recovery Stage of Septic Shock (NA)
- Evaluation of the Efficacy of rhBNP in Patients With Diuretic Resistance After Cardiac Surgery (NA)
- Metabolic Effects of Natriuretic Peptide Hormones (PHASE4)
- Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention
- rhBNP in Type 3 Pulmonary Hypertension (PHASE4)
- Effect of rhBNP on CMD in Patients With STEMI After PPCI (NA)
- Preliminary Study on the Clinical Effect of Recombinant Human Brain Natriuretic Peptide on Sepsis Complicated With Heart Failure (NA)
- Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: